0001104659-19-031227.txt : 20190522 0001104659-19-031227.hdr.sgml : 20190522 20190522213958 ACCESSION NUMBER: 0001104659-19-031227 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190522 FILED AS OF DATE: 20190522 DATE AS OF CHANGE: 20190522 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Vertex Global Healthcare Fund I Pte Ltd. CENTRAL INDEX KEY: 0001663140 STATE OF INCORPORATION: U0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38916 FILM NUMBER: 19847799 BUSINESS ADDRESS: STREET 1: 250 NORTH BRIDGE ROAD STREET 2: #05-01 RAFFLES CITY TOWER CITY: SINGAPORE STATE: U0 ZIP: 179101 BUSINESS PHONE: 6568288088 MAIL ADDRESS: STREET 1: 250 NORTH BRIDGE ROAD STREET 2: #05-01 RAFFLES CITY TOWER CITY: SINGAPORE STATE: U0 ZIP: 179101 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BICYCLE THERAPEUTICS Ltd CENTRAL INDEX KEY: 0001761612 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 BUSINESS ADDRESS: STREET 1: B900 BABRAHAM RESEARCH CAMPUS CITY: CAMBRIDGE STATE: X0 ZIP: CB22 3AT BUSINESS PHONE: 011441223261503 MAIL ADDRESS: STREET 1: B900 BABRAHAM RESEARCH CAMPUS CITY: CAMBRIDGE STATE: X0 ZIP: CB22 3AT 3 1 a3.xml 3 X0206 3 2019-05-22 0 0001761612 BICYCLE THERAPEUTICS Ltd BCYC 0001663140 Vertex Global Healthcare Fund I Pte Ltd. C/O BICYCLE THERAPEUTICS PLC B900, BABRAHAM RESEARCH CAMPUS CAMBRIDGE X0 CB22 3AT UNITED KINGDOM 0 0 1 0 Series B1 Preferred Shares Ordinary Shares 1272733 D Series B1 Preferred Shares Warrants 2025-03-31 Series B1 Preferred Shares 141668 D Series B2 Preferred Shares Ordinary Shares 206767 D Each Series B1 Preferred Share shall automatically convert into Ordinary Shares on a one for 1.429 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date. Share numbers give effect to the bonus shares issued to each holder of ordinary shares on the basis of 1.429 bonus shares for each ordinary share in issue, effective on May 13, 2019, which will be effective for the ordinary shares upon their conversion to ordinary shares upon the closing of the Issuer's initial public offering. The number of shares reflects the conversion of the Series B1 Preferred Shares and the Series B2 Preferred Shares to Ordinary Shares set out in footnotes (1) and (4). The Warrants to purchase Series B1 Preferred Shares have an exercise price of a nominal value per share. The Warrants are immediately exercisable and expire on March 31, 2025. Each Series B2 Preferred Share shall automatically convert into Ordinary Shares on a one for 1.429 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date. Name: /s/ Chua Kee Lock Title: Director 2019-05-22